Literature DB >> 19262115

Gene therapy for high-grade glioma: current approaches and future directions.

Atsushi Natsume1, Jun Yoshida.   

Abstract

The treatment of high-grade gliomas remains difficult despite recent advances in surgery, radiotherapy and chemotherapy. True advances may emerge from the increasing understanding in molecular biology and discovery of novel mechanisms for the delivery of tumoricidal agents. In an attempt to overcome this formidable neoplasm, molecular approaches using gene therapy have been investigated clinically since 1992. The clinical trials have mainly been classified into three approaches: suicide gene therapy, immune gene therapy and oncolytic viral therapy. In this article, we review these approaches, which have been studied in previous and ongoing clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 19262115      PMCID: PMC2634089          DOI: 10.4161/cam.2.3.6278

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  39 in total

Review 1.  Second-generation interferons for cancer: clinical targets.

Authors:  E C Borden; D Lindner; R Dreicer; M Hussein; D Peereboom
Journal:  Semin Cancer Biol       Date:  2000-04       Impact factor: 15.707

2.  Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor.

Authors:  K Asaoka; M Tada; Y Sawamura; J Ikeda; H Abe
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

3.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

Authors:  N G Rainov
Journal:  Hum Gene Ther       Date:  2000-11-20       Impact factor: 5.695

4.  IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma.

Authors:  A Natsume; K Tsujimura; M Mizuno; T Takahashi; J Yoshida
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

5.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Authors:  R Rampling; G Cruickshank; V Papanastassiou; J Nicoll; D Hadley; D Brennan; R Petty; A MacLean; J Harland; E McKie; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

6.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

7.  The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

Authors:  V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

8.  A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.

Authors:  Toshihiko Wakabayashi; Atsushi Natsume; Yoshio Hashizume; Masazumi Fujii; Masaaki Mizuno; Jun Yoshida
Journal:  J Gene Med       Date:  2008-04       Impact factor: 4.565

Review 9.  Molecular biology of glioma tumorigenesis.

Authors:  M L Ware; M S Berger; D K Binder
Journal:  Histol Histopathol       Date:  2003-01       Impact factor: 2.303

10.  Transduction of a fiber-mutant adenovirus for the HSVtk gene highly augments the cytopathic effect towards gliomas.

Authors:  N Shinoura; S Sakurai; A Asai; T Kirino; H Hamada
Journal:  Jpn J Cancer Res       Date:  2000-10
View more
  12 in total

1.  Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.

Authors:  Nadimpalli Ravi S Varma; Kenneth N Barton; Branislava Janic; Adarsh Shankar; Asm Iskander; Meser M Ali; Ali S Arbab
Journal:  World J Clin Oncol       Date:  2013-11-10

2.  Strategies in gene therapy for glioblastoma.

Authors:  Aneta Kwiatkowska; Mohan S Nandhu; Prajna Behera; E Antonio Chiocca; Mariano S Viapiano
Journal:  Cancers (Basel)       Date:  2013-10-23       Impact factor: 6.639

3.  Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.

Authors:  George E Naoum; Zeng B Zhu; Donald J Buchsbaum; David T Curiel; Waleed O Arafat
Journal:  Clin Transl Med       Date:  2017-03-01

4.  Innovative approaches for cancer treatment: current perspectives and new challenges.

Authors:  Carlotta Pucci; Chiara Martinelli; Gianni Ciofani
Journal:  Ecancermedicalscience       Date:  2019

Review 5.  Current Approaches for Glioma Gene Therapy and Virotherapy.

Authors:  Kaushik Banerjee; Felipe J Núñez; Santiago Haase; Brandon L McClellan; Syed M Faisal; Stephen V Carney; Jin Yu; Mahmoud S Alghamri; Antonela S Asad; Alejandro J Nicola Candia; Maria Luisa Varela; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Front Mol Neurosci       Date:  2021-03-11       Impact factor: 5.639

Review 6.  Gene therapy for malignant glioma.

Authors:  Hidehiro Okura; Christian A Smith; James T Rutka
Journal:  Mol Cell Ther       Date:  2014-07-08

7.  Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma.

Authors:  Martin J Hicks; Maria J Chiuchiolo; Douglas Ballon; Jonathan P Dyke; Eric Aronowitz; Kosuke Funato; Viviane Tabar; David Havlicek; Fan Fan; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 8.  A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?

Authors:  T C Hirst; H M Vesterinen; S Conlin; K J Egan; A Antonic; A Lawson McLean; M R Macleod; R Grant; P M Brennan; E S Sena; I R Whittle
Journal:  Evid Based Preclin Med       Date:  2015-01-20

9.  Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Authors:  Justyna Magdalena Przystal; Sajee Waramit; Md Zahidul Islam Pranjol; Wenqing Yan; Grace Chu; Aitthiphon Chongchai; Gargi Samarth; Nagore Gene Olaciregui; Ghazaleh Tabatabai; Angel Montero Carcaboso; Eric Ofori Aboagye; Keittisak Suwan; Amin Hajitou
Journal:  EMBO Mol Med       Date:  2019-04       Impact factor: 12.137

Review 10.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.